J. Morganroth

发表

Dealing with Global Safety Issues

N. Stockbridge, C. Garnett, R. Shah, 2013, Drug Safety.

Computer Recognition of Cardiac Arrhythmias and Statistical Approaches to Arrhythmia Analysis

J. Morganroth, 1984, Annals of the New York Academy of Sciences.

Pharmacologic management of ventricular arrhythmias after the cardiac arrhythmia suppression trial.

J. Bigger, J. Morganroth, Jr Jt Bigger, 1990, The American journal of cardiology.

J. Goin, J. Morganroth, 1991, Circulation.

Comparative left ventricular dimensions in trained athletes.

W. Henry, B. Maron, S. Epstein, 1975, Annals of internal medicine.

Relation between Echocardiographically Determined Left Atrial Size and Atrial Fibrillation

W. Henry, A. Pearlman, S. Epstein, 1976, Circulation.

Electrocardiographic Identification of Drug‐Induced QT Prolongation: Assessment by Different Recording and Measurement Methods

Borje Darpo, Nenad Sarapa, Wojciech Zareba, 2004, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

A review of the cardiac systemic side‐effects of antihistamines: ebastine

A. Moss, J. Morganroth, P. Chaikin, 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

No cardiac effects of therapeutic and supratherapeutic doses of rupatadine: results from a 'thorough QT/QTc study' performed according to ICH guidelines.

R. Antonijoan, M. Barbanoj, J. Morganroth, 2010, British journal of clinical pharmacology.

New concepts in cardiac imaging 1985

James L. Ritchie, Charles B. Higgins, C. Higgins, 1985 .

Cardiac Effects of Ebastine and Other Antihistamines in Humans

A. Moss, J. Morganroth, 1999, Drug safety.

Lack of Effect of Azelastine and Ketoconazole Coadministration on Electrocardiographic Parameters in Healthy Volunteers

W. Trager, J. Morganroth, R. Levy, 1997, Journal of clinical pharmacology.

The contributions of ambulatory ECG.

E. Michelson, J. Morganroth, 1979, Geriatrics.

Silent myocardial ischemia as a mechanism of sudden cardiac death.

J. Morganroth, M. D. Meissner, 1986, Cardiology clinics.

Effect of angiotensin converting enzyme inhibition on the incidence of restenosis after percutaneous transluminal coronary angioplasty.

R. Gottlieb, J. Morganroth, F. Brozovich, 1991, Catheterization and cardiovascular diagnosis.

Cardiac hypertrophy in response to dynamic conditioning in female athletes.

J. Morganroth, S. Zeldis, S. Rubler, 1978, Journal of applied physiology: respiratory, environmental and exercise physiology.

What are the Recommendations to the Medical Community to Institute Hypolipidemic Therapy

J. Morganroth, 1989 .

Type III hyperlipoproteinemia: an analysis of two contemporary definitions.

R. Levy, D. Fredrickson, J. Morganroth, 1975, Annals of internal medicine.

Mitral annular calcification: clinical, pathophysiology, and echocardiographic review.

J. Ross, N. DePace, M. Kotler, 1984, American heart journal.

Effects of a New Antibacterial, Telavancin, on Cardiac Repolarization (QTc Interval Duration) in Healthy Subjects

J. Morganroth, S. Barriere, D. Hoelscher, 2004, Journal of clinical pharmacology.

R‐wave Amplitude Variations During Acute Experimental Myocardial Ischemia: An Inadequate Index for Changes in Intracardiac Volume

E. Michelson, J. Morganroth, D. David, 1981, Circulation.

Echocardiography in the Differential Diagnosis of Patients with Chest Pain

I. Panidis, J. Morganroth, 1988 .

Noninvasive testing for ventricular arrhythmias.

J. Morganroth, 1988, Postgraduate medicine.

Short‐ and Long‐Term Therapeutic Efficacy of Quinidine Sulfate for the Treatment of Chronic Ventricular Arrhythmias

I. Panidis, J. Morganroth, 1982, Journal of clinical pharmacology.

New Criteria to Enhance the Predictability of Coronary Artery Disease by Exercise Testing in Asymptomatic Subjects

E. Lozner, J. Morganroth, L. Sturm, 1977, Circulation.

Prediction of cardiac death in patients with a very low ejection fraction after myocardial infarction: a Cardiac Arrhythmia Suppression Trial (CAST) study.

A. Waldo, R. Josephson, R. Chahine, 1995, American heart journal.

The biochemical, clinical, and genetic features of type III hyperlipoproteinemia.

R. Levy, D. Fredrickson, J. Morganroth, 1975, Annals of internal medicine.

Effect of propranolol on ventricular arrhythmia. The beta-blocker heart attack trial experience.

R. Harrist, J. Morganroth, E. Lichstein, 1983, Circulation.

Can we prevent sudden cardiac death?

L. Horowitz, J. Morganroth, 1982, The American journal of cardiology.

The value of echocardiographic regional wall motion abnormalities in detecting coronary artery disease in patients with or without a dilated left ventricle.

G. Mintz, R. Medina, I. Panidis, 1985, American heart journal.

Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease.

L. Horowitz, S. Spielman, B. Segal, 1985, The American journal of cardiology.

Acute severe aortic regurgitation. Pathophysiology, clinical recognition, and management.

J. Perloff, J. Morganroth, W. B. Dunkman, 1977, Annals of internal medicine.

Early recognition of surgically correctable causes of excessive mediastinal bleeding after coronary artery bypass graft surgery.

E. Michelson, J. Morganroth, H. Macvaugh, 1980, American journal of surgery.

Early and late proarrhythmia from antiarrhythmic drug therapy

J. Morganroth, 1992, Cardiovascular Drugs and Therapy.

Indications for antiarrhythmic suppression of ventricular arrhythmias: a definition of life-threatening ventricular arrhythmias.

J. Morganroth, 1993, The American journal of cardiology.

Proarrhythmic effects of antiarrhythmic drugs: evolving concepts.

J. Morganroth, 1992, American heart journal.

Placement of moricizine in the selection of antiarrhythmic drug therapy.

J. Morganroth, 1990, The American journal of cardiology.

Antiarrhythmic effects of beta-adrenergic blocking agents in benign or potentially lethal ventricular arrhythmias.

J. Morganroth, 1987, The American journal of cardiology.

The cardiac pharmacodynamics of therapeutic doses of sparfloxacin.

G. Talbot, J. Morganroth, M. Dorr, 1999, Clinical therapeutics.

Therapy with conventional antiarrhythmic drugs for ventricular arrhythmias.

N. DePace, J. Morganroth, P. Nestico, 1984, The Medical clinics of North America.

Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives

R. Shah, J. Morganroth, D. Shah, 2013, Drug Safety.

Ischemia at rest is independent of the extent of ventricular dysfunction and arrhythmias in patients with coronary artery disease.

L. Horowitz, A. Iskandrian, J. Morganroth, 1985, American heart journal.

Acute severe mitral regurgitation. Pathophysiology, clinical recognition, and management.

N. DePace, J. Morganroth, P. Nestico, 1985, The American journal of medicine.

Determinants of Ventricular Septal Motion: Influence of Relative Right and Left Ventricular Size

W. Henry, A. Pearlman, S. Epstein, 1976 .

EFFECT OF PROPRANOLOL ON VENTRICULAR ARRHYTHMIA/Lichstein et al

R. Harrist, J. Morganroth, E. Lichstein, 2005 .

Intravenous atenolol for ventricular arrhythmias.

J. Morganroth, 1986, The American journal of cardiology.

Role of Beta-Blocking Agents in the Treatment of Ventricular Arrhythmias

J. Morganroth, 1985 .

Sudden Cardiac Death and Congestive Heart Failure: Diagnosis and Treatment

E. Moore, J. Morganroth, 1983, Developments in Cardiovascular Medicine.

The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty.

T. Kreulen, H. Kasparian, R. Gottlieb, 1992, American heart journal.

Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram.

L. Horowitz, J. Morganroth, Joel Morganroth, 1984, The American journal of cardiology.

Ambulatory Holter electrocardiography: choice of technologies and clinical uses.

J. Morganroth, 1985, Annals of internal medicine.

Laboratory findings in pulmonary embolism.

K. Powell, J. Dalen, A. Deisseroth, 1971, Annals of internal medicine.

Pseudohomozygous type II hyperlipoproteinemia.

A. Gotto, R. Levy, J. Morganroth, 1974, The Journal of pediatrics.

Ambulatory electrocardiographic monitoring in the evaluation of new antiarrhythmic drugs.

J. Morganroth, 1986, Circulation.

THE ATHLETE'S HEART SYNDROME: A NEW PERSPECTIVE

B. Maron, J. Morganroth, 1977, Annals of the New York Academy of Sciences.

A Thorough Electrocardiogram Study of Edoxaban, a Novel Factor Xa Inhibitor

J. Morganroth, J. Mendell, A. Draves, 2011, Journal of clinical pharmacology.

Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide.

J. Anderson, J. Morganroth, G. Gentzkow, 1986, Journal of the American College of Cardiology.

Antiarrhythmic drug therapy 1988: for whom, how and where?

L. Horowitz, J. Morganroth, 1988, The American journal of cardiology.

Noninvasive diagnosis of the cardiomyopathies.

J. Morganroth, C. C. Chen, 1980, The Medical clinics of North America.

Beta-Blocker Heart Attack Trial: impact of propranolol therapy on ventricular arrhythmias.

R. Byington, J. Morganroth, E. Lichstein, 1985, Preventive medicine.

Influence of left ventricular dysfunction on flecainide therapy.

L. Horowitz, S. Spielman, A. Greenspan, 1987, Journal of the American College of Cardiology.

Development of congestive heart failure and alterations in left ventricular function in patients with sustained ventricular tachyarrhythmias treated with amiodarone.

L. Horowitz, S. Spielman, A. Greenspan, 1987, The American journal of cardiology.

ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies.

R. Shah, J. Morganroth, R. Kleiman, 2015, British journal of clinical pharmacology.

Dose effect of moricizine on suppression of ventricular arrhythmias.

J. Morganroth, 1990, The American journal of cardiology.

Aspirin- and coumadin-related bleeding after coronary- artery bypass graft surgery.

E. Michelson, J. Morganroth, H. Macvaugh, 1978, Annals of internal medicine.

Comparative efficacy and safety of oral tocainide and quinidine for benign and potentially lethal ventricular arrhythmias.

P. Steele, J. Morganroth, C. Oshrain, 1985, The American journal of cardiology.

Identification of the Patient at High Risk of Sudden Cardiac Death

J. Morganroth, 1983 .

Identification of sotalol-induced changes in repolarization with T wave area-based repolarization duration parameters.

Borje Darpo, Nenad Sarapa, Wojciech Zareba, 2003, Journal of electrocardiology.

Comparative efficacy and tolerance of esmolol to propranolol for control of supraventricular tachyarrhythmia.

L. Horowitz, J. Morganroth, P. Turlapaty, 1985, The American journal of cardiology.

Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval.

J. Morganroth, P. Chaikin, M. Gillen, 2001, British journal of clinical pharmacology.

Idiopathic left ventricular hypertrophy.

W. Henry, S. Epstein, J. Morganroth, 1974, The New England journal of medicine.

Exercise cross-sectional echocardiographic diagnosis of coronary artery disease.

J. Morganroth, H. Sawin, M. Naito, 1980, The American journal of cardiology.

Eletrocardiographic Monitoring in COPD Patients Receiving Tiotropium

J. Morganroth, W. Golisch, S. Kesten, 2004, COPD.

Echocardiographic detection of coronary artery disease. Detection of effects of ischemia on regional myocardial wall motion and visualization of left main coronary artery disease.

J. Morganroth, M. Naito, T. Mardelli, 1980, The American journal of cardiology.

Dilated cardiomyopathy in the idiopathic hypereosinophilic syndrome.

J. Ross, G. Mintz, N. DePace, 1983, The American journal of cardiology.

Application of a frequency definition of ventricular proarrhythmia.

M. Borland, J. Morganroth, G. Chao, 1987, The American journal of cardiology.

Initiating events of sudden cardiac death.

I. Panidis, J. Morganroth, 1985, Cardiovascular clinics.

QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.

K. Dooley, A. Diacon, G. Maartens, 2021, The Lancet. Infectious diseases.

Evaluation of vardenafil and sildenafil on cardiac repolarization.

Timothy H. Montague, G. Dabiri, V. Sethuraman, 2004, The American journal of cardiology.

A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.

A. Anzueto, M. Niederman, J. Dimarco, 2005, Chest.

Relation of preoperative use of aspirin to increased mediastinal blood loss after coronary artery bypass graft surgery.

E. Michelson, J. Morganroth, M. Torosian, 1978, The Journal of thoracic and cardiovascular surgery.

Fascicular conduction disturbances after coronary bypass surgery

L. Horowitz, M. Josephson, J. Kastor, 1978 .

Risk factors for the development of proarrhythmic events.

J. Morganroth, 1987, The American journal of cardiology.

Cellular and humoral sensitivity to gluten fractions in patients with treated nontropical sprue

J. Morganroth, A. B. French, D. Watson, 1972, The American Journal of Digestive Diseases.

A new approach to visualize the left main coronary artery using apical cross-sectional echocardiography.

Y. Nakamura, L. Dreifus, M. Akaishi, 1980, The American journal of cardiology.

Influence of Left Ventricular Dysfunctlon on Flecainide Therapy

L. Horowitz, S. Spielman, A. Greenspan, 2010 .

Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase.

T. Strom, A. Deisseroth, C. Carpenter, 1972, Proceedings of the National Academy of Sciences of the United States of America.

Detecting Left Main Coronary Artery Disease by Apical, Cross‐sectional Echocardiography

J. Morganroth, S. Ogawa, T. Mardelli, 1980, Circulation.

Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval).

G. Talbot, J. Morganroth, M. Dorr, 1999, Clinical therapeutics.

Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma

J. Burke, I. Flinn, J. Morganroth, 2015, Cancer Chemotherapy and Pharmacology.

Determination of antiarrhythmic drug efficacy in the treatment of ventricular arrhythmias

J. Morganroth, 1990, Cardiovascular Drugs and Therapy.

Replacing the thorough QT study: reflections of a baby in the bath water.

R. Shah, J. Morganroth, R. Kleiman, 2014, British journal of clinical pharmacology.

Editorial Review Drug-Induced Cardiac Toxicity: Emphasizing the Role of Electrocardiography in Clinical Research and Drug Development

I. Gussak, J. Morganroth, R. Kleiman, 2004 .

Evaluation and Management of Cardiac Safety Using the Electrocardiogram in Oncology Clinical Trials: Focus on Cardiac Repolarization (QTc Interval)

R. Shah, J. Morganroth, R. Shah, 2010, Clinical pharmacology and therapeutics.

Familial type III hyperlipoproteinemia.

R. Levy, J. Morganroth, 1977, Annals of internal medicine.

Flecainide: steady state electrophysiologic effects in patients with remote myocardial infarction and inducible sustained ventricular arrhythmia.

L. Horowitz, S. Spielman, A. Greenspan, 1986, Journal of the American College of Cardiology.

ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies.

R. Shah, J. Morganroth, 2013, British journal of clinical pharmacology.

Modulation of Cytotoxic T Lymphocyte Function by Cyclic 3′,5′-Mononucleotides

T. Strom, A. Deisseroth, C. Carpenter, 1974 .

Sudden death during ambulatory electrocardiographic monitoring.

S. Gottlieb, C. Pepine, J. Morganroth, 1991, The American journal of cardiology.

A rational approach to the planning and analysis of electrocardiogram safety data in clinical trials

S. Steare, J. Morganroth, 2002, International Journal of Pharmaceutical Medicine.

Electrocardiographic evidence of left ventricular hypertrophy in otherwise normal children. Clarification by echocardiography.

L. J. Krovetz, W. Henry, B. Maron, 1975, The American journal of cardiology.

New Antiarrhythmic Drugs

L. Horowitz, J. Morganroth, P. Nestico, 1988, Drugs.

Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias.

L. Horowitz, J. Morganroth, 1985, The American journal of cardiology.

Calcification of the tricuspid anulus diagnosed by two-dimensional echocardiography.

J. Ross, G. Mintz, I. Panidis, 1984, American heart journal.

Atrial alternans: experimental echocardiographic and hemodynamic demonstration during programmed pacing.

E. Michelson, J. Morganroth, M. Naito, 1981, The American journal of cardiology.

Usefulness of ambulatory monitoring of blood pressure in assessing antihypertensive therapy.

W. White, J. Morganroth, 1989, The American journal of cardiology.

Treatment of hyperlipidemia.

B. Rifkind, R. Levy, J. Morganroth, 1974, The New England journal of medicine.

Echocardiographic features of atrioventricular and ventriculoatrial conduction.

E. Michelson, L. Dreifus, J. Morganroth, 1980, The American journal of cardiology.

Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia

E. Moore, J. Morganroth, 1990, Developments in Cardiovascular Medicine.

Apex sector echocardiography in evaluation of the right atrium in patients with mitral stenosis and atrial septal defect.

W. Lam, F. Kushner, J. Morganroth, 1978, The American journal of cardiology.

Arrhythmias in Patients With Chronic Obstructive Pulmonary Disease (COPD): Occurrence Frequency and the Effect of Treatment With the Inhaled Long-Acting Beta2-Agonists Arformoterol and Salmeterol

P. Zimetbaum, J. Hanrahan, J. Morganroth, 2008, Medicine.

Wide-complex tachycardias: recognition and management.

J. Morganroth, S. Kutalek, Joel Morganroth, 1988, Hospital practice.

Cross-sectional echocardiographic detection of aortic valve prolapse.

J. Morganroth, M. Naito, T. Mardelli, 1980, American heart journal.

Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms.

J. Morganroth, 1993, The American journal of cardiology.

Noninvasive evaluation of normal and abnormal prosthetic valve function.

J. Ross, G. Mintz, I. Panidis, 1983, Journal of the American College of Cardiology.

Prosthetic mitral valve motion during cardiac dysrhythmias as determined by echocardiography.

I. Panidis, M. Kotler, J. Morganroth, 1983, The American journal of cardiology.

Embolized disc from a Beall mitral valve prosthesis. Real-time echocardiographic identification.

J. Morganroth, C. C. Chen, F. J. Pauletto, 1982, Chest.

Beta-adrenergic blockade by nadolol in control of ventricular tachyarrhythmias.

K. Nademanee, B. Singh, J. Morganroth, 1984, American heart journal.

Two dimensional echocardiography in mitral, aortic and tricuspid valve prolapse. The clinical problem, cardiac nuclear imaging considerations and a proposed standard for diagnosis.

R. Jones, J. Morganroth, M. Naito, 1980, The American journal of cardiology.

Tricuspid valve prolapse diagnosed by cross-sectional echocardiography.

J. Morganroth, M. Naito, T. Mardelli, 1981, Chest.

Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group.

G. Talbot, J. Morganroth, P. Jaillon, 1996, The Journal of antimicrobial chemotherapy.

Cardiac Arrhythmias: New Therapeutic Drugs and Devices

E. Moore, J. Morganroth, 1985, Developments in Cardiovascular Medicine.

Exercise performance after septal myotomy and myectomy in patients with obstructive hypertrophic cardiomyopathy.

J. Hirshfeld, S. Epstein, J. Borer, 1979, The American journal of cardiology.

Bupivacaine Extended-Release Liposome Injection Exhibits a Favorable Cardiac Safety Profile

S. Bergese, E. Onel, J. Morganroth, 2011, Regional Anesthesia & Pain Medicine.

7 – The Pharmacology of Antiarrhythmic Drugs

J. Morganroth, P. Nestico, 1986 .

Cardiac arrhythmias in the elderly: antiarrhythmic drug treatment.

J. Morganroth, P. Nestico, 1986, Cardiology clinics.

Changes in the Corneal Reflex in Patients Wearing Contact Lenses

L. Richman, J. Morganroth, 1969 .

Telavancin versus Standard Therapy for Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: FAST 2 Study

V. Fowler, W. O'Riordan, J. Morganroth, 2006, Antimicrobial Agents and Chemotherapy.

SV40 Virus-induced Tumour Specific Transplantation Antigen in Cultured Mouse Cells

P. Mora, J. Morganroth, Richard Smith, 1970, Nature.

Cardiac Repolarization and the Safety of New Drugs Defined by Electrocardiography

J. Morganroth, 2007, Clinical pharmacology and therapeutics.

Antiarrhythmic agents and their use in therapy.

L. Dreifus, J. Morganroth, 1980, Pharmacology & therapeutics.

The use of the Doppler stethoscope in the evaluation of varicoceles.

A. Wein, L. Lipshultz, J. Morganroth, 1977, The Journal of urology.

Electrocardiographic Findings in Patients with Obstructive and Nonobstructive Hypertrophic Cardiomyopathy

L. Horowitz, M. Josephson, E. Michelson, 1978, Circulation.

Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial.

P. Schellhammer, D. Lamm, H. Grossman, 1996, Urology.

Pharmacokinetics of moricizine HCl.

D. Mason, R. Williams, F. Mcmahon, 1987, The American journal of cardiology.

Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)

R. Shah, J. Morganroth, D. Shah, 2013, Drug Safety.

Mechanism and prevention of cardiac arrhythmias in chronic hemodialysis patients.

E. Michelson, J. Morganroth, Steven Brown, 1980, Kidney international.

Differentiation of carcinomatous and bacterial meningitis

P. Schein, A. Deisseroth, J. Morganroth, 1972, Neurology.

The Evaluation of New Antiarrhythmic Drugs

Joel Morganroth, Leonard S. Dreifus, E. Moore, 1981, Developments in Cardiovascular Medicine.

Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials

S. Ripa, J. Morganroth, S. Colucci, 2017, Postgraduate medicine.

Fixed coupling: different mechanisms revealed by exercise-induced changes in cycle length.

J. Spear, M. Josephson, J. Kastor, 1978, Circulation.

Interventions in the Acute Phase of Myocardial Infarction

Joel Morganroth, E. Moore, J. Morganroth, 2011, Developments in Cardiovascular Medicine.

Cibenzoline plasma concentration and antiarrhythmic effect

N. Carliner, J. Heger, J. Somberg, 1984, Clinical pharmacology and therapeutics.

Class IC Antiarrhythmic Agents: Status — 1984

J. Morganroth, 1985 .

Efficacy and safety of intravenous tocainide compared with intravenous lidocaine for acute ventricular arrhythmias immediately after cardiac surgery.

I. Panidis, E. Smith, J. Morganroth, 1984, The American journal of cardiology.

A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment.

Joel Morganroth, J. Morganroth, 2004, Journal of electrocardiology.

Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit

R. Shah, J. Morganroth, 2015, Drug Safety.

Isolated dextroversion of the heart with asymmetric septal hypertrophy.

M. Josephson, A. Buxton, J. Perloff, 1976, American heart journal.

Electrocardiographic left atrial enlargement. Electrophysiologic, echocardiographic and hemodynamic correlates.

M. Josephson, J. Kastor, J. Morganroth, 1977, The American journal of cardiology.

Unsuspected substantial pericardial effusions detected by echocardiography.

A. Riba, J. Morganroth, 1976, JAMA.

Thallium-201 imaging in pericardial effusion.

A. Hakki, A. Iskandrian, J. Morganroth, 1986, Clinical nuclear medicine.

Acute severe pulmonic valve regurgitation: pathophysiology, diagnosis, and treatment.

N. DePace, A. Iskandrian, J. Morganroth, 1984, American heart journal.

Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin.

J. Ronan, R. Dibianco, J. Morganroth, 1984, American heart journal.

Myocardial oxygen supply/demand ratio in aortic stenosis: hemodynamic and echocardiographic evaluation of patients with and without angina pectoris.

N. DePace, J. Ren, A. Hakki, 1983, Journal of the American College of Cardiology.

Determinants of ventricular septal motion. Influence of relative right and left ventricular size.

W. Henry, A. Pearlman, S. Epstein, 1976, Circulation.

Tricuspid regurgitation: noninvasive techniques for determining causes and severity.

J. Ross, G. Mintz, N. DePace, 1984, Journal of the American College of Cardiology.

Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis.

I. Panidis, J. Morganroth, C. Baessler, 1983, The American journal of cardiology.

Discrete fibromembranous aortic stenosis in middle age. Natural history and case report.

J. Perloff, A. Greenspan, J. Morganroth, 1979, Cardiology.

The Evaluation of Beta Blocker and Calcium Antagonist Drugs

Joel Morganroth, E. Moore, J. Morganroth, 1982, Developments in Cardiovascular Medicine.

Mechanisms and risk factors for proarrhythmia with type Ia compared with Ic antiarrhythmic drug therapy.

A. Kadish, J. Levine, J. Morganroth, 1989, Circulation.

Long-Term Ambulatory Electrocardiographic Recording in the Determination of Efficacy of New Antiarrhythmic Agents

Joel Morganroth, J. Morganroth, 1981 .

New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the cardiac arrhythmia suppression trial and its pilot study

P. Denes, D. Wyse, A. Hallstrom, 1994 .

New Insights into the Drug Treatment of Ventricular Arrhythmias

J. Morganroth, P. Nestico, 1984, International journal of dermatology.

Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy.

L. Horowitz, G. Mintz, S. Spielman, 1985, Journal of the American College of Cardiology.

Sensitivity to atypical mycobacterial antigens in patients with Crohn's disease

J. Morganroth, D. Watson, 1970, The American Journal of Digestive Diseases.

Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents

E. Moore, J. Morganroth, 2011, Developments in Cardiovascular Medicine.

Postoperative arrhythmias after coronary artery and cardiac valvular surgery detected by long-term electrocardiographic monitoring.

E. Michelson, J. Morganroth, H. Macvaugh, 1979, American heart journal.

Tyrosine Kinase Inhibitors: Their On-Target Toxicities as Potential Indicators of Efficacy

Joel Morganroth, R. Shah, J. Morganroth, 2013, Drug Safety.

A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease

L. Rabinovich, E. Samara, J. Morganroth, 2019, Clinical pharmacology in drug development.

Asymptomatic Coronary Artery Disease: Angiographic Assessment ofDiabetics Evaluated forRenalTransplantation

L. Grauer, J. Morganroth, C. Clark, 1978 .

Nonsustained ventricular tachycardia in ambulatory patients: characteristics and association with sudden cardiac death.

E. Michelson, J. Morganroth, W. Follansbee, 1980, Annals of internal medicine.

Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia.

J. Morganroth, F. Brozovich, J Morganroth, 1991, The American journal of cardiology.

Large mobile pedunculated left ventricular thrombus: Identification by two‐dimensional echocardiography

J. Morganroth, C. C. Chen, G. Webster, 1981, Clinical cardiology.

Spontaneous Variability of Complex Ventricular Arrhythmias Detected by Long‐term Electrocardiographic Recording

E. Michelson, J. Morganroth, E L Michelson, 1980, Circulation.

Immediate Diagnosis of Acute Myocardial Infarction by Two‐dimensional Echocardiography

R. Horowitz, J. Morganroth, J. Soffer, 1982, Circulation.

Two Dimensional Echocardiography in Acute Myocardial Infarction: Clinical Applications

I. Panidis, J. Morganroth, 1984 .

Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability.

J. Ruskin, S. Ruberg, C. Pratt, 1996, American heart journal.

Electrophysiologic testing in patients at high risk for sudden cardiac death. I. Nonsustained ventricular tachycardia and abnormal ventricular function.

L. Horowitz, S. Spielman, A. Greenspan, 1985, Journal of the American College of Cardiology.

Encainide for ventricular arrhythmias: placebo-controlled and standard comparison trials.

J. Morganroth, 1986, The American journal of cardiology.

Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias.

P. Hsu, D. Salerno, J. Somberg, 1986, Journal of the American College of Cardiology.

Flecainide: a new antiarrhythmic agent.

J. Morganroth, P. Nestico, 1986, American family physician.

Management of ventricular arrhythmias in patients with congestive heart failure. Second case history presentation and panel discussion.

J. Morganroth, 1986, The American journal of cardiology.

Immediate detection of early high-risk patients with acute myocardial infarction using two-dimensional echocardiographic evaluation of left ventricular regional wall motion abnormalities.

R. Horowitz, J. Morganroth, R. S. Horowitz, 1982, American heart journal.

Class IV Antiarrhythmic Agents: Utility in Supraventricular Arrhythmias and Their Proarrhythmic Potential

L. Horowitz, J. Morganroth, 1989 .

Drug-induced cardiac toxicity: emphasizing the role of electrocardiography in clinical research and drug development.

Joel Morganroth, I. Gussak, J. Morganroth, 2004, Journal of electrocardiology.

Discrepancy between the QRS scoring system and left ventricular ejection fraction after surgical or medical revascularization during acute myocardial infarction.

N. DePace, A. Iskandrian, J. Morganroth, 1984, The American journal of cardiology.

Sudden death in hospitalized patients: cardiac rhythm disturbances detected by ambulatory electrocardiographic monitoring.

I. Panidis, J. Morganroth, J Morganroth, 1983, Journal of the American College of Cardiology.

Proarrhythmia, arrhythmogenesis or aggravation of arrhythmia--a status report, 1987.

L. Horowitz, J. Bigger, M. Rosen, 1987, The American journal of cardiology.

Evaluating the QT-Liability of a Drug during its Development

R. Shah, J. Morganroth, 2008, Pharmaceutical Medicine.

Short-to-Medium-Term Treatment of Ventricular Arrhythmias

J. Goin, J. Morganroth, 2005 .

Superior QRS axis of ventricular premature complexes: an additional criterion to enhance the sensitivity of exercise stress testing.

L. Dreifus, J. Morganroth, T. Mardelli, 1980, The American journal of cardiology.

Tricuspid regurgitation in tricuspid valve prolapse demonstrated with contrast cross-sectional echocardiography.

J. Morganroth, M. Naito, T. Mardelli, 1980, The American journal of cardiology.

Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers

J. Morganroth, K. Flaharty, C. Moresino, 2015, Supportive Care in Cancer.

Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects

M. Lefkowitz, C. Dunger-Baldauf, J. Morganroth, 2002, American Journal of Gastroenterology.

1156 POSTER High dose palonosetron does not alter ECG parameters including QTc interval in healthy subjects: results of a dose-response, double blind, randomized, parallel E14 study of palonosetron vs. moxifloxacin or placebo

J. Morganroth, M. Thorn, M. Cullen, 2007 .

Ethmozin: a new antiarrhythmic agent developed in the USSR. Efficacy and tolerance.

L. Horowitz, M. Josephson, E. Michelson, 1979, American heart journal.

A review of the uses and limitations of tocainide--a class IB antiarrhythmic agent.

L. Horowitz, J. Morganroth, P. Nestico, 1985, American heart journal.

Tocainide: a new oral antiarrhythmic agent.

L. Horowitz, J. Morganroth, S. Kutalek, 1985, Annals of internal medicine.

The clinical electrophysiology of intravenous indecainide.

L. Horowitz, S. Spielman, A. Greenspan, 1985, American heart journal.

Safety and efficacy of a twice-daily dosing regimen for moricizine (ethmozine).

J. Morganroth, 1985, American heart journal.

Cholestyramine: an effective, twice-daily dosage regimen.

R. Havlik, C. Blum, J. Morganroth, 1976, Annals of internal medicine.

Apical cross-sectional echocardiography. Standard for the diagnosis of idiopathic mitral valve prolapse syndrome.

J. Morganroth, M. Naito, T. Mardelli, 1981, Chest.

Cardiovascular complaints. Correlation with cardiac arrhythmias on 24-hour electrocardiographic monitoring.

E. Michelson, J. Morganroth, S. Zeldis, 1980, Chest.

Retinal arteriolar changes as an indicator of coronary artery disease.

E. Michelson, J. Morganroth, H. Macvaugh, 1979, Archives of internal medicine.

Treatment of ventricular arrhythmias by United States cardiologists: a survey before the Cardiac Arrhythmia Suppression Trial results were available.

J. Bigger, J. Anderson, J. Morganroth, 1990, The American journal of cardiology.

Premature ventricular complexes. Diagnosis and indications for therapy.

J. Morganroth, 1984, JAMA.

Beta Blocking Agents in the Treatment of Ventricular Arrhythmias

J. Morganroth, 1982 .

Holter monitoring and sudden cardiac death

Joel Morganroth, I. Panidis, J. Morganroth, 1992 .

The effects of benazepril, a new angiotensin‐converting enzyme inhibitor, in mild to moderate essential hypertension: A multicenter study

J. Mckenney, A. Leon, M. Sambhi, 1991, Clinical pharmacology and therapeutics.

Comparative Evaluation of Àntiarrhythmic Agents

J. Morganroth, 2012, Drugs.

Effects of the Selective α1A‐Adrenoceptor Antagonist Silodosin on ECGs of Healthy Men in a Randomized, Double‐Blind, Placebo‐ and Moxifloxacin‐Controlled Study

H. Lepor, L. Hill, J. Morganroth, 2010, Clinical pharmacology and therapeutics.

Noninvasive approaches to cardiac imaging: comparisons and contrasts.

G. Pohost, J. Morganroth, 1980, The American journal of cardiology.

Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients.

A L Waldo, Y Pawitan, Y. Pawitan, 1991, Journal of the American College of Cardiology.

Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers

Robert Harrell, J. Morganroth, Yanfeng Wang, 2012, Cancer Chemotherapy and Pharmacology.

Short Term Evaluation of Atenolol in Hospitalised Patients with Chronic Ventricular Arrhythmias

J. Morganroth, 1983, Drugs.

Ambulatory ischemia and sudden death: An analysis of 35 cases of death during ambulatory ECG monitoring

S. Gottlieb, C. Pepine, J. Morganroth, 1991 .

Infective endocarditis involving a presumably normal pulmonic valve.

J. Ross, N. DePace, S. Mattleman, 1984, American Journal of Cardiology.

Systemic concentrations of salbutamol and HFA-134a after inhalation of salbutamol sulfate in a chlorofluorocarbon-free system.

J. Morganroth, L. Harrison, B. Ekholm, 1996, Therapeutic drug monitoring.

Benefits of Centralized ECG Reading in Clinical Oncology Studies

J. Morganroth, R. Kleiman, J. Litwin, 2016, Therapeutic innovation & regulatory science.

Effects of Food on the Bioequivalence of Different Verapamil Sustained‐Release Formulations

S. Waldman, J. Morganroth, 1995, Journal of clinical pharmacology.

Oral verapamil in the treatment of atrial fibrillation/flutter

L. Dreifus, J. Morganroth, S. Sturm, 1982 .

Sensitivity in detecting drug-induced alterations in the PR interval: comparison of the surface electrocardiogram measured by a cardiologist versus routine automated computer analysis.

S. Waldman, J. Morganroth, 1993, The American journal of cardiology.

Variability of the QTc interval: impact on defining drug effect and low-frequency cardiac event.

D L Kunze, W. Crumb, A. Brown, 1993, The American journal of cardiology.

Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study

J. Morganroth, S. Hollenbach, U. Sinha, 2013, Expert opinion on pharmacotherapy.

Quinidine-induced liver disease.

A. Deisseroth, J. Morganroth, S. Winokur, 1972, Annals of internal medicine.

Intramyocardial Conduction: A Major Determinant of R‐wave Amplitude During Acute Myocardial Ischemia

E. Michelson, J. Morganroth, DANIEL DAVID, 1982, Circulation.

Dose-response range of encainide for benign and potentially lethal ventricular arrhythmias.

P. Hsu, P. Pool, J. Morganroth, 1986, The American journal of cardiology.

Double-blind comparison of doxazosin, nadolol, and placebo in patients with mild-to-moderate hypertension

L. Svetkey, P. Deedwania, R. Graham, 1988 .

Diagnostic accuracy of seismocardiography compared with electrocardiography for the anatomic and physiologic diagnosis of coronary artery disease during exercise testing.

R A Wilson, V S Bamrah, M Schwaiger, 1993, The American journal of cardiology.

The Pharmacokinetics and Safety of Single Escalating Oral Doses of Eletriptan

J. Morganroth, S. Harris, Ajit K. Shah, 2002, Journal of clinical pharmacology.

Effects of intravenous infusion of esmolol and propranolol on biventricular performance at rest and during exercise as assessed by quantitative radionuclide angiography.

A. Hakki, A. Iskandrian, J. Morganroth, 1985, The American journal of cardiology.

Electrocardiographic Effects of Rivastigmine

J. Morganroth, R. Anand, R. Hartman, 2002, Journal of clinical pharmacology.

Single‐Dose Pharmacokinetics and Dose Proportionality of Oral Cibenzoline

W. Colburn, J. Morganroth, K. Khoo, 1984, Journal of clinical pharmacology.

Efficacy and tolerance of Ethmozine (moricizine HCl) in placebo-controlled trials.

H. Kennedy, D. Mason, C. Pratt, 1987, The American journal of cardiology.

A definitive study of the effects of PDE‐5 inhibitors on cardiac repolarization in middle‐age males

G. Dabiri, V. Sethuraman, J. Morganroth, 2004 .

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

K. Dooley, A. Diacon, G. Maartens, 2022, Clinical pharmacology and therapeutics.

Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias.

J. Morganroth, 1987, The American journal of cardiology.

Bepridil hydrochloride for treatment of benign or potentially lethal ventricular arrhythmias.

C. Mulhern, L. Horowitz, J. Morganroth, 1986, American Journal of Cardiology.

Nicardipine versus placebo for the treatment of postoperative hypertension.

J. S. Goldberg, J. Seltzer, N. Halpern, 1988, American heart journal.

Comparative efficacy and safety of short-acting and sustained release quinidine in the treatment of patients with ventricular arrhythmias.

J. Morganroth, H. Hunter, 1985, American heart journal.

The syndromes of familial atrioventricular block with sinus bradycardia: prognostic indices, electrophysiologic and histopathologic correlates.

J. Morganroth, Schneider, Roller Dh, 1978, European journal of cardiology.

Relation between Echocardiographically Determined Left Atrial Size and Atrial Fibrillation

W. Henry, A. Pearlman, S. Epstein, 1976, Circulation.

Early Investigation of QTc Liability

Joel Morganroth, R. Shah, J. Morganroth, 2012, Drug Safety.

Early investigation of QTc liability: the role of multiple ascending dose (MAD) study.

Joel Morganroth, R. Shah, J. Morganroth, 2012, Drug safety.

Clinical Experience with Moxifloxacin in Patients with Respiratory Tract Infections

G. Faich, J. Morganroth, S. Kowalsky, 2004, The Annals of Pharmacotherapy.

Do Beta Blockers Prevent Sudden Cardiac Death

J. Morganroth, 1983 .

Efficacy and safety of esmolol vs propranolol in the treatment of supraventricular tachyarrhythmias: a multicenter double-blind clinical trial.

J Abrams, A. Waldo, J. Anderson, 1985, American heart journal.

Second generation antiarrhythmic agents: have we reached antiarrhythmic Nirvana?

L. Horowitz, J. Morganroth, 1987, Journal of the American College of Cardiology.

Tegaserod of its Use in the Management of Irritable Bowel Syndrome with Constipation in Women

Y. Ringel, J. Morganroth, K. Bardhan, 2003 .

Effect of orally administered celiprolol in patients with chronic atrial fibrillation.

J. Atwood, N. Mostow, J. Morganroth, 1986, Journal of cardiovascular pharmacology.

Effectiveness of low-dose nadolol for ventricular arrhythmias.

J. Morganroth, K. Duchin, 1986, The American journal of cardiology.

Premature ventricular complexes. Diagnosis and indications for therapy.

J. Morganroth, 1984, JAMA.